Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
Harrow (NASDAQ: HROW), a leading North American eyecare pharmaceutical company, has announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Conference on August 13, 2025.
CEO Mark L. Baum and CFO Andrew Boll will participate in a fireside chat at 8:30 a.m. ET. Additionally, Baum will join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET. Both sessions will be available via webcast on the company's website, with replays accessible for 90 days after the event.
Harrow (NASDAQ: HROW), un'azienda leader nel settore farmaceutico oftalmico del Nord America, ha annunciato la sua partecipazione al prossimo 5潞 Congresso Annuale di Oftalmologia H.C. Wainwright che si terr脿 il 13 agosto 2025.
Il CEO Mark L. Baum e il CFO Andrew Boll parteciperanno a una conversazione informale alle 8:30 a.m. ET. Inoltre, Baum prender脿 parte a un panel di discussione su "Trattamenti Innovativi per le Patologie dell'Anteriore dell'Occhio" alle 1:00 p.m. ET. Entrambe le sessioni saranno trasmesse in webcast sul sito web dell'azienda, con repliche disponibili per 90 giorni dopo l'evento.
Harrow (NASDAQ: HROW), una destacada empresa farmac茅utica oftalmol贸gica en Norteam茅rica, ha anunciado su participaci贸n en la pr贸xima 5陋 Conferencia Anual de Oftalmolog铆a H.C. Wainwright el 13 de agosto de 2025.
El CEO Mark L. Baum y el CFO Andrew Boll participar谩n en una charla informal a las 8:30 a.m. ET. Adem谩s, Baum formar谩 parte de un panel de discusi贸n sobre "Nuevos Tratamientos para Indicaciones en la Parte Frontal del Ojo" a la 1:00 p.m. ET. Ambas sesiones estar谩n disponibles v铆a webcast en el sitio web de la compa帽铆a, con repeticiones accesibles durante 90 d铆as posteriores al evento.
Harrow (NASDAQ: HROW)電� 攵侂毳� 靹犽弰頃橂姅 鞎堦臣 鞝滌暯 須岇偓搿滌劀, 雼り皜鞓る姅 H.C. Wainwright 鞝�5須� 鞐半 鞎堦臣 旎嵓霟办姢鞐� 2025雲� 8鞗� 13鞚� 彀戈皜頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟.
CEO Mark L. Baum瓿� CFO Andrew Boll鞚� 霃欕秬鞁滉皠 鞓れ爠 8鞁� 30攵�鞐� 歆勴枆霅橂姅 雽�雼挫棎 彀胳棳頃╇媹雼�. 霕愴暅 Baum鞚� 霃欕秬鞁滉皠 鞓ろ泟 1鞁�鞐� "鞝勳晥攵� 歆堩櫂鞚� 鞙勴暅 靸堧鞖� 旃橂氩�"鞐� 甏�頃� 韺剱 韱犽鞐愲弰 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 霊� 靹胳厴 氇憪 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 膦呺 頉� 90鞚� 霃欖晥 雼れ嫓氤搓赴 臧�電ロ暕雼堧嫟.
Harrow (NASDAQ : HROW), une entreprise pharmaceutique nord-am茅ricaine de premier plan dans le domaine des soins oculaires, a annonc茅 sa participation 脿 la prochaine 5e Conf茅rence Annuelle d'Ophtalmologie H.C. Wainwright qui aura lieu le 13 ao没t 2025.
Le PDG Mark L. Baum et le directeur financier Andrew Boll participeront 脿 une discussion informelle 脿 8h30 ET. De plus, Baum prendra part 脿 un panel sur "Nouveaux traitements pour les indications de la partie ant茅rieure de l'艙il" 脿 13h00 ET. Les deux sessions seront diffus茅es en webcast sur le site de l'entreprise, avec des rediffusions accessibles pendant 90 jours apr猫s l'茅v茅nement.
Harrow (NASDAQ: HROW), ein f眉hrendes nordamerikanisches Pharmaunternehmen im Bereich Augenheilkunde, hat seine Teilnahme an der bevorstehenden 5. J盲hrlichen Ophthalmologie-Konferenz von H.C. Wainwright am 13. August 2025 bekannt gegeben.
CEO Mark L. Baum und CFO Andrew Boll werden an einem Fireside-Chat um 8:30 Uhr ET teilnehmen. Zus盲tzlich wird Baum an einer Podiumsdiskussion zum Thema 鈥濶eue Behandlungen f眉r Erkrankungen der vorderen Augenpartien鈥� um 13:00 Uhr ET teilnehmen. Beide Sitzungen werden per Webcast auf der Unternehmenswebsite verf眉gbar sein, mit Wiedergaben, die 90 Tage nach der Veranstaltung abrufbar sind.
- None.
- None.
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright鈥檚 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.
Harrow鈥檚 Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on 鈥淣ovel Treatments for Front-of-the-Eye Indications鈥� at 1 p.m. Eastern time.
Both the and the will be webcast live and can be found on the Company鈥檚 website. A replay will be on the website for approximately 90 days following the event.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit .
Contact:
Mike Biega, Vice President of Investor Relations and Communications
617-913-8890
FAQ
When is Harrow (HROW) presenting at the H.C. Wainwright Ophthalmology Conference 2025?
Who will be representing Harrow at the H.C. Wainwright Conference?
How can investors access Harrow's H.C. Wainwright Conference presentation?
What topics will Harrow (HROW) discuss at the H.C. Wainwright Conference?
